Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.49 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL28328677 | 0.94 | KYNU (0.89) | KYNUHIF1ALMNAKDM4EGRIA2 | |
| SCHEMBL9064883 | 0.83 | KYNU (0.70) | KYNULMNAGRM2GRM3 | |
| SCHEMBL3581364 | 0.83 | KYNU (0.70) | KYNULMNAGRM2GRM3 | |
| SCHEMBL9065063 | 0.83 | KYNU (0.70) | KYNULMNAGRM2GRM3 | |
| SCHEMBL9065025 | 0.83 | KYNU (0.70) | KYNULMNAGRM2GRM3 | |
| SCHEMBL25712023 | 0.81 | KYNU (0.68) | KYNUHIF1ALMNAKDM4EADRB1 | |
| SCHEMBL27665730 | 0.80 | KYNU (0.67) | KYNUHIF1ALMNAKDM4EGRIA2 | |
| SCHEMBL27643924 | 0.80 | KYNU (0.67) | KYNUHIF1ALMNAKDM4EGRIA2 | |
| SCHEMBL27278720 | 0.79 | KYNU (0.65) | KYNUHIF1ALMNAKDM4EADRB1 | |
| SCHEMBL27643934 | 0.77 | KYNU (0.62) | KYNUHIF1ALMNAKDM4EGRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280047-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | claimed |
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-05-11 | — | — | US | claimed |
| US-11376248-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-07-05 | — | — | US | claimed |
| US-20200138810-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-05-07 | — | — | US | claimed |
| WO-2019006384-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-01-03 | — | — | WO | claimed |
| US-12280047-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-11896615-B2 | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators | JUNO THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4190335-A1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | Juno Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-3525803-B1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | JUNO THERAPEUTICS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11376248-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11376248-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200138810-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200138810-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| WO-2019006384-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2536713-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | Pfizer Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2011101774-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | KYNU, HAAO, HCAR2 | KYNU 1/4885HIF1A 1861/4885LMNA 600/4885 |
| US-11896615-B2 | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators | KYNU, IDO1, IDO2 | KYNU 1/4885HIF1A 1559/4885LMNA 4001/4885 |
| US-12280047-B2 | Treatment of aneurysms | KYNU, HAAO, HCAR2 | KYNU 1/4885HIF1A 1861/4885LMNA 600/4885 |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | HTR4, HTR1A, HTR3B | KYNU 289/4885HIF1A 3764/4885LMNA 4257/4885 |
| US-11376248-B2 | Treatment of aneurysms | KYNU, HAAO, HCAR2 | KYNU 1/4885HIF1A 1861/4885LMNA 600/4885 |
| US-20200138810-A1 | TREATMENT OF ANEURYSMS | KYNU, HAAO, HCAR2 | KYNU 1/4885HIF1A 1861/4885LMNA 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.